Artelo Biosciences (ARTL) Non Operating Investment Income (2021 - 2024)
Artelo Biosciences (ARTL) posted quarterly Non Operating Investment Income of -$248000.0 for Q4 2024, down 248.5% year-over-year from $167000.0 in Q1 2024, and down 493.65% quarter-over-quarter from $63000.0 in Q3 2024.
Artelo Biosciences (ARTL) Non Operating Investment Income (2021 - 2024) Analysis & Trends
Artelo Biosciences (ARTL) has reported Non Operating Investment Income for 4 consecutive years, with -$248000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Non Operating Investment Income fell 248.5% year-over-year to -$248000.0; the TTM figure through Sep 2024 stood at $415000.0 (down 32.08% YoY), while the FY2025 annual figure was $22000.0, changed N/A from the prior year.
- Non Operating Investment Income retreated to -$248000.0 in Q4 2024 per ARTL's latest filing, from $63000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $185000.0 in Q2 2023 and bottomed at -$248000.0 in Q4 2024.
- Historically, Non Operating Investment Income has averaged $70776.6 across 4 years, with a median of $92500.0 in 2024.
- Annual changes were most pronounced in 2023 — Non Operating Investment Income jumped 139.13% — and 2024, when it sank 248.5%.
- Artelo Biosciences' Non Operating Investment Income stood at $984.0 in 2021, then soared by 13822.76% to $137000.0 in 2022, then grew by 21.9% to $167000.0 in 2023, then tumbled by 248.5% to -$248000.0 in 2024.
- Business Quant data shows ARTL's Non Operating Investment Income at -$248000.0 in Q4 2024, $63000.0 in Q3 2024, and $79000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -248,000.00 |
| Dec 31, 2024 | -248,000.00 |
| Sep 30, 2024 | 63,000.00 |
| Sep 30, 2024 | 63,000.00 |
| Jun 30, 2024 | 79,000.00 |
| Jun 30, 2024 | 79,000.00 |
| Mar 31, 2024 | 106,000.00 |
| Mar 31, 2024 | 106,000.00 |
| Dec 31, 2023 | 167,000.00 |
| Dec 31, 2023 | 167,000.00 |
| Sep 30, 2023 | 165,000.00 |
| Sep 30, 2023 | 165,000.00 |
| Jun 30, 2023 | 185,000.00 |
| Jun 30, 2023 | 185,000.00 |
| Mar 31, 2023 | 124,000.00 |
| Mar 31, 2023 | 124,000.00 |
| Dec 31, 2022 | 137,000.00 |
| Dec 31, 2022 | 137,000.00 |
| Sep 30, 2022 | 69,000.00 |
| Sep 30, 2022 | 69,000.00 |